Unicycive Therapeutics, Inc. financial data

Symbol
UNCY on Nasdaq
Industry
Pharmaceutical Preparations
Location
4300 El Camino Real, Suite 210, Los Altos, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 206 % +48.8%
Quick Ratio 25.1 %
Debt-to-equity -477 % -188%
Return On Equity 603 % +69%
Return On Assets -61.4 % +60.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 104M shares +199%
Common Stock, Shares, Outstanding 97.9M shares +182%
Entity Public Float 19.5M USD +56.2%
Common Stock, Value, Issued 98K USD +180%
Weighted Average Number of Shares Outstanding, Basic 88.9M shares +173%
Weighted Average Number of Shares Outstanding, Diluted 88.9M shares +173%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 675K USD
Research and Development Expense 19M USD +51.6%
General and Administrative Expense 10.2M USD +28.4%
Operating Income (Loss) -29.2M USD -47.4%
Nonoperating Income (Expense) 2.16M USD +34.3%
Net Income (Loss) Attributable to Parent -23M USD +18.1%
Earnings Per Share, Basic -0.47 USD/shares +73%
Earnings Per Share, Diluted -0.7 USD/shares +59.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.3M USD +105%
Inventory, Net 3.11M USD +56.6%
Assets, Current 37.7M USD +103%
Property, Plant and Equipment, Net 61K USD +118%
Operating Lease, Right-of-Use Asset 772K USD -8.64%
Assets 38.6M USD +98.4%
Accounts Payable, Current 548K USD -49.4%
Accrued Liabilities, Current 2.99M USD +18.3%
Liabilities, Current 10.5M USD -32.3%
Operating Lease, Liability, Noncurrent 265K USD -52%
Liabilities 10.7M USD -33%
Retained Earnings (Accumulated Deficit) -79.7M USD -40.5%
Stockholders' Equity Attributable to Parent 27.9M USD +711%
Liabilities and Equity 38.6M USD +98.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.46M USD -64.7%
Net Cash Provided by (Used in) Financing Activities 45.7M USD +64.4%
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 97.9M shares +182%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32.3M USD +125%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5M USD
Deferred Tax Assets, Valuation Allowance 11.2M USD +50.3%
Deferred Tax Assets, Gross 11.3M USD +51.8%
Operating Lease, Liability 807K USD
Depreciation 9K USD +350%
Payments to Acquire Property, Plant, and Equipment 6K USD
Lessee, Operating Lease, Liability, to be Paid 871K USD
Property, Plant and Equipment, Gross 92K USD +119%
Operating Lease, Liability, Current 542K USD +72.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 608K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 64K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 72K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.98M USD +43.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.9M shares +32708%
Unrecognized Tax Benefits 1.03M USD +48.8%
Additional Paid in Capital 107M USD +78.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 161K USD +403%
Share-based Payment Arrangement, Expense 2.32M USD -34.9%
Interest Expense 90K USD +66.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%